Virtus LifeSci Biotech Clinical Trials ETF (BBC)Health | Exchange Traded Fund | NYSEArca
53.29 USD
-2.04
(-3.694%) ⇩
(Aug. 28, 2026, 3:50 p.m.
EDT)
After hours: 53.29 |
Hot Take ↕ | Aug. 22, 2026, 2:19 a.m. EDT
The clinical trials ETF is currently exhibiting a classic 'bottom-fishing' momentum pattern. After a brutal multi-year decline where the asset lost nearly half its value in 2022 and continued to bleed in 2023 and 2025, the price has finally staged a technical recovery, surging past its 52-week highs recently. However, the long-term outlook remains murky; the business has suffered four consecutive years of negative annual returns, and the market has punished this structural deterioration by driving the price down significantly despite the recent rally. The recent surge appears to be a relief rally rather than a fundamental reversal, evidenced by the weak statistical forecast confidence and the lack of broad-based options speculation. While the short-term trend is clearly bullish with strong relative strength against moving averages, investors should remain cautious that the underlying asset quality has not yet proven itself resilient enough to sustain a long-term bull case. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.037532 |
| MSTL | 0.045162 |
| AutoARIMA | 0.051891 |
| AutoETS | 0.051892 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 47% |
| H-stat | 0.91 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.556 |
| Excess Kurtosis | -0.58 |
As of Aug. 22, 2026, 2:19 a.m. EDT: Speculator positioning is extremely thin and fragmented across expirations. In the near term (August), there is a distinct volume spike in calls at the $48 strike, suggesting a speculative bet on a bounce or gap-up, while put activity is negligible. For the October expiration, open interest is heavily concentrated in the money at lower strikes ($45 and $50), indicating a defensive stance or hedging against further downside rather than a bullish breakout. Implied volatility is generally low, reflecting a lack of consensus on immediate direction.
| Last Yield | 1yr Yield | 3yr Avg | 5yr Avg |
|---|---|---|---|
| 1.63% | 1.63% | 1.00% | 0.60% |
| Date | Dividend | Yield % |
|---|---|---|
| 2025-12-22 | 0.655 | 1.630164 |
| 2024-12-20 | 0.240 | 0.986518 |
| 2023-12-20 | 0.082 | 0.368705 |
| 2017-12-20 | 0.297 | 1.084337 |
| 2015-12-21 | 0.147 | 0.504288 |
| Attribute | Value |
|---|---|
| All Time High | 62.6 |
| All Time Low | 13.42 |
| Ask | 55.37 |
| Ask Size | 300 |
| Average Daily Volume10 Day | 21,490 |
| Average Daily Volume3 Month | 22,720 |
| Average Volume | 22,720 |
| Average Volume10Days | 21,490 |
| Beta3 Year | 1.26 |
| Bid | 53.25 |
| Bid Size | 300 |
| Category | Health |
| Crypto Tradeable | 0 |
| Currency | USD |
| Custom Price Alert Confidence | HIGH |
| Day High | 54.42 |
| Day Low | 53.2 |
| Dividend Date | 1,514,332,800 |
| Dividend Yield | 1.34 |
| Esg Populated | 0 |
| Exchange | PCX |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 51.74642 |
| Fifty Day Average Change | 1.5476799 |
| Fifty Day Average Change Percent | 0.029908925 |
| Fifty Two Week Change Percent | 129.71552 |
| Fifty Two Week High | 56.18 |
| Fifty Two Week High Change | -2.8858986 |
| Fifty Two Week High Change Percent | -0.051368788 |
| Fifty Two Week Low | 22.825 |
| Fifty Two Week Low Change | 30.4691 |
| Fifty Two Week Low Change Percent | 1.3349004 |
| Fifty Two Week Range | 22.825 - 56.18 |
| First Trade Date Milliseconds | 1,418,826,600,000 |
| Five Year Average Return | 0.0373641 |
| Full Exchange Name | NYSEArca |
| Fullday Change | -2.0441 |
| Fullday Change Percent | -3.69383 |
| Fullday Price | 53.2941 |
| Fund Family | Virtus |
| Fund Inception Date | 1,418,688,000 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Has Pre Post Market Data | 1 |
| Language | en-US |
| Legal Type | Exchange Traded Fund |
| Long Business Summary | Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering ("lead drug") that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval. |
| Long Name | Virtus LifeSci Biotech Clinical Trials ETF |
| Market | us_market |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_274653436 |
| Nav Price | 55.14972 |
| Net Assets | 46,390,104.0 |
| Net Expense Ratio | 0.65 |
| Open | 55.56 |
| Phone | (212) 593-4383 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 53.2941 |
| Post Market Time | 1,787,959,805 |
| Previous Close | 55.3382 |
| Price Hint | 2 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | ETF |
| Region | US |
| Regular Market Change | -2.0441 |
| Regular Market Change Percent | -3.69383 |
| Regular Market Day High | 54.42 |
| Regular Market Day Low | 53.2 |
| Regular Market Day Range | 53.2 - 54.42 |
| Regular Market Open | 55.56 |
| Regular Market Previous Close | 55.3382 |
| Regular Market Price | 53.2941 |
| Regular Market Time | 1,787,946,601 |
| Regular Market Volume | 18,256 |
| Short Name | Virtus Biotech Clinical Trials |
| Source Interval | 15 |
| Symbol | BBC |
| Three Year Average Return | 0.3837139 |
| Total Assets | 46,390,104 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Peg Ratio | None |
| Trailing Three Month Nav Returns | 11.18185 |
| Trailing Three Month Returns | 11.18185 |
| Triggerable | 1 |
| Two Hundred Day Average | 43.77232 |
| Two Hundred Day Average Change | 9.521782 |
| Two Hundred Day Average Change Percent | 0.21752976 |
| Type Disp | ETF |
| Volume | 18,256 |
| Yield | 0.0134000005 |
| Ytd Return | 26.24431 |